These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

809 related items for PubMed ID: 17499425

  • 1. hK2 and free PSA, a prognostic combination in predicting minimal prostate cancer in screen-detected men within the PSA range 4-10 ng/ml.
    Raaijmakers R, de Vries SH, Blijenberg BG, Wildhagen MF, Postma R, Bangma CH, Darte C, Schröder FH.
    Eur Urol; 2007 Nov; 52(5):1358-64. PubMed ID: 17499425
    [Abstract] [Full Text] [Related]

  • 2. Serum human glandular kallikrein 2 (hK2) for distinguishing stage and grade of prostate cancer.
    Stephan C, Jung K, Nakamura T, Yousef GM, Kristiansen G, Diamandis EP.
    Int J Urol; 2006 Mar; 13(3):238-43. PubMed ID: 16643616
    [Abstract] [Full Text] [Related]

  • 3. Cancer detection and cancer characteristics in the European Randomized Study of Screening for Prostate Cancer (ERSPC)--Section Rotterdam. A comparison of two rounds of screening.
    Postma R, Schröder FH, van Leenders GJ, Hoedemaeker RF, Vis AN, Roobol MJ, van der Kwast TH.
    Eur Urol; 2007 Jul; 52(1):89-97. PubMed ID: 17257742
    [Abstract] [Full Text] [Related]

  • 4. Similar rates of exponential decrease in serum concentrations of free prostate-specific antigen (PSA), PSA complexed to alpha-1-antichymotrypsin, and human glandular kallikrein 2 (hK2) in prostate cancer patients treated with GnRH-analogues.
    Björk T, Schalken J, Wittjes W, Ljungberg B, Lilja H.
    Prostate; 2001 Apr; 47(1):14-20. PubMed ID: 11304725
    [Abstract] [Full Text] [Related]

  • 5. Prospective detection of clinically relevant prostate cancer in the prostate specific antigen range 1 to 3 ng./ml. combined with free-to-total ratio 20% or less: the Aarau experience.
    Recker F, Kwiatkowski MK, Huber A, Stamm B, Lehmann K, Tscholl R.
    J Urol; 2001 Sep; 166(3):851-5. PubMed ID: 11490232
    [Abstract] [Full Text] [Related]

  • 6. The importance of human glandular kallikrein and its correlation with different prostate specific antigen serum forms in the detection of prostate carcinoma.
    Recker F, Kwiatkowski MK, Piironen T, Pettersson K, Lümmen G, Wernli M, Wiefelspütz J, Graber SF, Goepel M, Huber A, Tscholl R.
    Cancer; 1998 Dec 15; 83(12):2540-7. PubMed ID: 9874461
    [Abstract] [Full Text] [Related]

  • 7. Comparison of predictive accuracy for pathologically organ confined clinical stage T1c prostate cancer using human glandular kallikrein 2 and prostate specific antigen combined with clinical stage and Gleason grade.
    Haese A, Vaisanen V, Lilja H, Kattan MW, Rittenhouse HG, Pettersson K, Chan DW, Huland H, Sokoll LJ, Partin AW.
    J Urol; 2005 Mar 15; 173(3):752-6. PubMed ID: 15711262
    [Abstract] [Full Text] [Related]

  • 8. Discrimination of men with prostate cancer from those with benign disease by measurements of human glandular kallikrein 2 (HK2) in serum.
    Becker C, Piironen T, Pettersson K, Björk T, Wojno KJ, Oesterling JE, Lilja H.
    J Urol; 2000 Jan 15; 163(1):311-6. PubMed ID: 10604382
    [Abstract] [Full Text] [Related]

  • 9. The value of (-7, -5)pro-prostate-specific antigen and human kallikrein-2 as serum markers for grading prostate cancer.
    Bangma CH, Wildhagen MF, Yurdakul G, Schröder FH, Blijenberg BG.
    BJU Int; 2004 Apr 15; 93(6):720-4. PubMed ID: 15049979
    [Abstract] [Full Text] [Related]

  • 10. Should we replace the Gleason score with the amount of high-grade prostate cancer?
    Vis AN, Roemeling S, Kranse R, Schröder FH, van der Kwast TH.
    Eur Urol; 2007 Apr 15; 51(4):931-9. PubMed ID: 16935413
    [Abstract] [Full Text] [Related]

  • 11. Serum human glandular kallikrein (hK2) and insulin-like growth factor 1 (IGF-1) improve the discrimination between prostate cancer and benign prostatic hyperplasia in combination with total and %free PSA.
    Scorilas A, Plebani M, Mazza S, Basso D, Soosaipillai AR, Katsaros N, Pagano F, Diamandis EP.
    Prostate; 2003 Feb 15; 54(3):220-9. PubMed ID: 12518327
    [Abstract] [Full Text] [Related]

  • 12. Free and total human glandular kallikrein 2 in patients with prostate cancer.
    Väisänen V, Pettersson K, Alanen K, Viitanen T, Nurmi M.
    Urology; 2006 Jul 15; 68(1):219-25. PubMed ID: 16844459
    [Abstract] [Full Text] [Related]

  • 13. Preoperative blood reverse transcriptase-PCR assays for prostate-specific antigen and human glandular kallikrein for prediction of prostate cancer progression after radical prostatectomy.
    Shariat SF, Gottenger E, Nguyen C, Song W, Kattan MW, Andenoro J, Wheeler TM, Spencer DM, Slawin KM.
    Cancer Res; 2002 Oct 15; 62(20):5974-9. PubMed ID: 12384565
    [Abstract] [Full Text] [Related]

  • 14. Is it necessary to detect all prostate cancers in men with serum PSA levels <3.0 ng/ml? A comparison of biopsy results of PCPT and outcome-related information from ERSPC.
    Schröder FH, Bangma CH, Roobol MJ.
    Eur Urol; 2008 May 15; 53(5):901-8. PubMed ID: 18262712
    [Abstract] [Full Text] [Related]

  • 15. Clinical utility of human glandular kallikrein 2 within a neural network for prostate cancer detection.
    Stephan C, Jung K, Soosaipillai A, Yousef GM, Cammann H, Meyer H, Xu C, Diamandis EP.
    BJU Int; 2005 Sep 15; 96(4):521-7. PubMed ID: 16104903
    [Abstract] [Full Text] [Related]

  • 16. Association of free-prostate specific antigen subfractions and human glandular kallikrein 2 with volume of benign and malignant prostatic tissue.
    Steuber T, Niemela P, Haese A, Pettersson K, Erbersdobler A, Felix Chun KH, Graefen M, Kattan MW, Huland H, Lilja H.
    Prostate; 2005 Apr 01; 63(1):13-8. PubMed ID: 15378521
    [Abstract] [Full Text] [Related]

  • 17. Preoperative serum prostate specific antigen levels between 2 and 22 ng./ml. correlate poorly with post-radical prostatectomy cancer morphology: prostate specific antigen cure rates appear constant between 2 and 9 ng./ml.
    Stamey TA, Johnstone IM, McNeal JE, Lu AY, Yemoto CM.
    J Urol; 2002 Jan 01; 167(1):103-11. PubMed ID: 11743285
    [Abstract] [Full Text] [Related]

  • 18. Evaluation of proprostate specific antigen for early detection of prostate cancer in men with a total prostate specific antigen range of 4.0 to 10.0 ng/ml.
    Khan MA, Partin AW, Rittenhouse HG, Mikolajczyk SD, Sokoll LJ, Chan DW, Veltri RW.
    J Urol; 2003 Sep 01; 170(3):723-6. PubMed ID: 12913682
    [Abstract] [Full Text] [Related]

  • 19. Is additional testing necessary in men with prostate-specific antigen levels of 1.0 ng/mL or less in a population-based screening setting? (ERSPC, section Rotterdam).
    Roobol MJ, Roobol DW, Schröder FH.
    Urology; 2005 Feb 01; 65(2):343-6. PubMed ID: 15708050
    [Abstract] [Full Text] [Related]

  • 20. Detection of prostate specific transcripts in the peripheral blood during brachytherapy predicts postoperative PSA kinetics.
    Mabjeesh NJ, Amir S, Stenger A, Chen J, Matzkin H.
    Prostate; 2009 Aug 01; 69(11):1235-44. PubMed ID: 19434652
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 41.